{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:42:45Z","timestamp":1789180965179,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"DOI":"10.7759\/cureus.74469","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:33:34Z","timestamp":1732610014000},"source":"Crossref","is-referenced-by-count":1,"title":["Connecting the Dots: Exploring the Association Between Systemic Lupus Erythematosus and Thyroid Disorders"],"prefix":"10.7759","author":[{"given":"Syed Muhammad Hayyan","family":"Nishat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma A","family":"Alzaabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema M","family":"Alzaabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana J","family":"Al Tarawneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf J","family":"Al Tarawneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Abdul Muqsit","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabish W","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raqshan W","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiza W","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59111911","article-title":"Thyroid disease and systemic lupus erythematosus","volume":"59","author":"Athanassiou L","year":"2023","unstructured":"Athanassiou L, Kostoglou-Athanassiou I, Kaiafa G, et al.. Thyroid disease and systemic lupus erythematosus. Medicina (Kaunas). 2023, 59:1911. 10.3390\/medicina59111911","journal-title":"Medicina (Kaunas)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber MR","year":"2021","unstructured":"Barber MR, Drenkard C, Falasinnu T, et al.. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021, 17:515-32. 10.1038\/s41584-021-00668-1","journal-title":"Nat Rev Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi A","year":"2024","unstructured":"Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet. 2024, 403:2326-38. 10.1016\/S0140-6736(24)00398-2","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11105","article-title":"Thyroid disease in lupus: an updated review","volume":"2","author":"Klionsky Y","year":"2020","unstructured":"Klionsky Y, Antonelli M. Thyroid disease in lupus: an updated review. ACR Open Rheumatol. 2020, 2:74-8. 10.1002\/acr2.11105","journal-title":"ACR Open Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/injr.injr_165_19","article-title":"Prevalence of thyroid dysfunction in patients with systemic lupus erythematosus: a descriptive cross sectional study","volume":"15","author":"Shobha V","year":"2020","unstructured":"Shobha V, Desai A, Chandy S, Pakalomattom S. Prevalence of thyroid dysfunction in patients with systemic lupus erythematosus: a descriptive cross sectional study. Indian J Rheumatol. 2020, 15:79-83. 10.4103\/injr.injr_165_19","journal-title":"Indian J Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13089","article-title":"Hashimoto thyroiditis, anti-thyroid antibodies and systemic lupus erythematosus","volume":"21","author":"Posselt RT","year":"2018","unstructured":"Posselt RT, Coelho VN, Skare TL. Hashimoto thyroiditis, anti-thyroid antibodies and systemic lupus erythematosus. Int J Rheum Dis. 2018, 21:186-93. 10.1111\/1756-185X.13089","journal-title":"Int J Rheum Dis"},{"key":"ref7","article-title":"Graves Disease","author":"Pokhrel B","year":"2023","unstructured":"Pokhrel B, Bhusal K. Graves Disease. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4158\/EP161664.OR","article-title":"High prevalence of hypothyroidism in systemic lupus erythematosus patients without an increase in circulating anti-thyroid antibodies","volume":"23","author":"Domingues SL","year":"2017","unstructured":"Domingues SL, Gon\u00e7alves FT, Jorge ML, Limongi JE, Ranza R, Jorge PT. High prevalence of hypothyroidism in systemic lupus erythematosus patients without an increase in circulating anti-thyroid antibodies. Endocr Pract. 2017, 23:1304-10. 10.4158\/EP161664.OR","journal-title":"Endocr Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201827","article-title":"Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE","volume":"15","author":"Graham RR","year":"2007","unstructured":"Graham RR, Ortmann W, Rodine P, et al.. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet. 2007, 15:823-30. 10.1038\/sj.ejhg.5201827","journal-title":"Eur J Hum Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of human systemic lupus erythematosus: a cellular perspective","volume":"23","author":"Moulton VR","year":"2017","unstructured":"Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med. 2017, 23:615-35. 10.1016\/j.molmed.2017.05.006","journal-title":"Trends Mol Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2010.01.007","article-title":"Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis","volume":"30","author":"Ramos PS","year":"2010","unstructured":"Ramos PS, Brown EE, Kimberly RP, Langefeld CD. Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis. Semin Nephrol. 2010, 30:164-76. 10.1016\/j.semnephrol.2010.01.007","journal-title":"Semin Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.9771\/cmbio.v10i2.4825","article-title":"Human major histocompatibility complex and thyroid dysfunction in hepatitis C carries","volume":"10","author":"De Oliveira Andrade LJ","year":"2011","unstructured":"De Oliveira Andrade LJ, De Melo PRS, Fran\u00e7a LS, Fran\u00e7a LS, Malta AMA, Paran\u00e1 R. Human major histocompatibility complex and thyroid dysfunction in hepatitis C carries. Rev Ci\u00eancias M\u00e9d Biol. 2011, 10:179-86. 10.9771\/cmbio.v10i2.4825","journal-title":"Rev Ci\u00eancias M\u00e9d Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2000.00958.x","article-title":"Effective formation of major histocompatibility complex class II-peptide complexes from endogenous antigen by thyroid epithelial cells","volume":"99","author":"Maile R","year":"2000","unstructured":"Maile R, Elsegood KA, Harding TC, Uney JB, Stewart CE, Banting G, Dayan CM. Effective formation of major histocompatibility complex class II-peptide complexes from endogenous antigen by thyroid epithelial cells. Immunology. 2000, 99:367-74. 10.1046\/j.1365-2567.2000.00958.x","journal-title":"Immunology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003214","article-title":"Genetic dissection of HLA-DRB1*15:01 and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB1*15:01","volume":"9","author":"Kawasaki A","year":"2023","unstructured":"Kawasaki A, Kusumawati PA, Kawamura Y, et al.. Genetic dissection of HLA-DRB1*15:01 and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB1*15:01. RMD Open. 2023, 9:e003214. 10.1136\/rmdopen-2023-003214","journal-title":"RMD Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092492","article-title":"Actual associations between HLA haplotype and Graves' disease development","volume":"11","author":"Zawadzka-Starczewska K","year":"2022","unstructured":"Zawadzka-Starczewska K, Tymoniuk B, Stasiak B, Lewi\u0144ski A, Stasiak M. Actual associations between HLA haplotype and Graves' disease development. J Clin Med. 2022, 11:2492. 10.3390\/jcm11092492","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.972121","article-title":"Genetic basis of defects in immune tolerance underlying the development of autoimmunity","volume":"13","author":"Hocking AM","year":"2022","unstructured":"Hocking AM, Buckner JH. Genetic basis of defects in immune tolerance underlying the development of autoimmunity. Front Immunol. 2022, 13:972121. 10.3389\/fimmu.2022.972121","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2009.10.011","article-title":"The role of B cells in lupus pathogenesis","volume":"42","author":"Nashi E","year":"2010","unstructured":"Nashi E, Wang Y, Diamond B. The role of B cells in lupus pathogenesis. Int J Biochem Cell Biol. 2010, 42:543-50. 10.1016\/j.biocel.2009.10.011","journal-title":"Int J Biochem Cell Biol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042251","article-title":"Defective B cell tolerance checkpoints in systemic lupus erythematosus","volume":"201","author":"Yurasov S","year":"2005","unstructured":"Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005, 201:703-11. 10.1084\/jem.20042251","journal-title":"J Exp Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051190","article-title":"B cell activation and escape of tolerance checkpoints: recent insights from studying autoreactive B cells","volume":"10","author":"Bonasia CG","year":"2021","unstructured":"Bonasia CG, Abdulahad WH, Rutgers A, Heeringa P, Bos NA. B cell activation and escape of tolerance checkpoints: recent insights from studying autoreactive B cells. Cells. 2021, 10:1190. 10.3390\/cells10051190","journal-title":"Cells"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914413","article-title":"Cytokines in systemic lupus erythematosus-focus on TNF-\u03b1 and IL-17","volume":"24","author":"Richter P","year":"2023","unstructured":"Richter P, Macovei LA, Mihai IR, Cardoneanu A, Burlui MA, Rezus E. Cytokines in systemic lupus erythematosus-focus on TNF-\u03b1 and IL-17. Int J Mol Sci. 2023, 24:14413. 10.3390\/ijms241914413","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2003.11.002","article-title":"Th1\/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?","volume":"33","author":"G\u00f3mez D","year":"2004","unstructured":"G\u00f3mez D, Correa PA, G\u00f3mez LM, Cadena J, Molina JF, Anaya JM. Th1\/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?. Semin Arthritis Rheum. 2004, 33:404-13. 10.1016\/j.semarthrit.2003.11.002","journal-title":"Semin Arthritis Rheum"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.973813","article-title":"Boosting regulatory T cell function for the treatment of autoimmune diseases - that's only half the battle!","volume":"13","author":"Schl\u00f6der J","year":"2022","unstructured":"Schl\u00f6der J, Shahneh F, Schneider FJ, Wieschendorf B. Boosting regulatory T cell function for the treatment of autoimmune diseases - that's only half the battle!. Front Immunol. 2022, 13:973813. 10.3389\/fimmu.2022.973813","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal M","year":"2020","unstructured":"Postal M, Vivaldo JF, Fernandez-Ruiz R, Paredes JL, Appenzeller S, Niewold TB. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020, 67:87-94. 10.1016\/j.coi.2020.10.014","journal-title":"Curr Opin Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2011.0071","article-title":"Interferon alpha as a primary pathogenic factor in human lupus","volume":"31","author":"Niewold TB","year":"2011","unstructured":"Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res. 2011, 31:887-92. 10.1089\/jir.2011.0071","journal-title":"J Interferon Cytokine Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow MK","year":"2014","unstructured":"Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014, 192:5459-68. 10.4049\/jimmunol.1002795","journal-title":"J Immunol"},{"key":"ref26","article-title":"Changes of serum IL-6, IL-10 and TNF-\u03b1 levels in patients with systemic lupus erythematosus and their clinical value","volume":"13","author":"Jin S","year":"2021","unstructured":"Jin S, Yu C, Yu B. Changes of serum IL-6, IL-10 and TNF-\u03b1 levels in patients with systemic lupus erythematosus and their clinical value. Am J Transl Res. 2021, 13:2867-74.","journal-title":"Am J Transl Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-021-00879-x","article-title":"Hashimoto's thyroiditis and coexisting disorders in correlation with HLA status-an overview","volume":"173","author":"Mikosch P","year":"2023","unstructured":"Mikosch P, Aistleitner A, Oehrlein M, Trifina-Mikosch E. Hashimoto's thyroiditis and coexisting disorders in correlation with HLA status-an overview. Wien Med Wochenschr. 2023, 173:41-53. 10.1007\/s10354-021-00879-x","journal-title":"Wien Med Wochenschr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3934\/medsci.2023002","article-title":"Relationship between CTLA4, TNF-\u03b1 and PTPN22 gene polymorphism and the serum levels of antithyroglobulin and antiperoxidase antibodies in autoimmune thyroiditis","volume":"10","author":"Rahimova R","year":"2023","unstructured":"Rahimova R. Relationship between CTLA4, TNF-\u03b1 and PTPN22 gene polymorphism and the serum levels of antithyroglobulin and antiperoxidase antibodies in autoimmune thyroiditis. AIMS Med Sci. 2023, 10:14-23. 10.3934\/medsci.2023002","journal-title":"AIMS Med Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16222","article-title":"Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment","volume":"132","author":"Klubo-Gwiezdzinska J","year":"2022","unstructured":"Klubo-Gwiezdzinska J, Wartofsky L. Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment. Pol Arch Intern Med. 2022, 132:16222. 10.20452\/pamw.16222","journal-title":"Pol Arch Intern Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2011.0049","article-title":"Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity","volume":"31","author":"Ganesh BB","year":"2011","unstructured":"Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res. 2011, 31:721-31. 10.1089\/jir.2011.0049","journal-title":"J Interferon Cytokine Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-023-09848-8","article-title":"The genetics of Graves' disease","volume":"25","author":"Grixti L","year":"2024","unstructured":"Grixti L, Lane LC, Pearce SH. The genetics of Graves' disease. Rev Endocr Metab Disord. 2024, 25:203-14. 10.1007\/s11154-023-09848-8","journal-title":"Rev Endocr Metab Disord"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1007\/s004240000019","article-title":"Changes in Th1\/Th2 cytokine balance in Graves' disease","volume":"440","author":"Kocjan T","year":"2000","unstructured":"Kocjan T, Wraber B, Repnik U, Hojker S. Changes in Th1\/Th2 cytokine balance in Graves' disease. Pflugers Arch. 2000, 440:R94-5.","journal-title":"Pflugers Arch"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308090020","article-title":"The innate immune system in SLE: type I interferons and dendritic cells","volume":"17","author":"R\u00f6nnblom L","year":"2008","unstructured":"R\u00f6nnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus. 2008, 17:394-9. 10.1177\/0961203308090020","journal-title":"Lupus"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00238","article-title":"Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations","volume":"4","author":"Mavragani CP","year":"2013","unstructured":"Mavragani CP, Niewold TB, Chatzigeorgiou A, et al.. Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations. Front Immunol. 2013, 4:238. 10.3389\/fimmu.2013.00238","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00578","article-title":"Autoimmunity-related risk variants in PTPN22 and CTLA4 are associated with ME\/CFS with infectious onset","volume":"11","author":"Steiner S","year":"2020","unstructured":"Steiner S, Becker SC, Hartwig J, et al.. Autoimmunity-related risk variants in PTPN22 and CTLA4 are associated with ME\/CFS with infectious onset. Front Immunol. 2020, 11:578. 10.3389\/fimmu.2020.00578","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of systemic lupus erythematosus","volume":"16","author":"Pan L","year":"2020","unstructured":"Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020, 16:19-30. 10.1007\/s12519-019-00229-3","journal-title":"World J Pediatr"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-21-0024","article-title":"Cellular and molecular basis of thyroid autoimmunity","volume":"11","author":"Bogus\u0142awska J","year":"2022","unstructured":"Bogus\u0142awska J, Godlewska M, Gajda E, Piekie\u0142ko-Witkowska A. Cellular and molecular basis of thyroid autoimmunity. Eur Thyroid J. 2022, 11:e210024. 10.1530\/ETJ-21-0024","journal-title":"Eur Thyroid J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/432595","article-title":"Inflammatory cytokines in systemic lupus erythematosus","volume":"2011","author":"Ohl K","year":"2011","unstructured":"Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2011, 2011:432595. 10.1155\/2011\/432595","journal-title":"J Biomed Biotechnol"},{"key":"ref39","article-title":"Hashimoto Thyroiditis","author":"Mincer DL","year":"2024","unstructured":"Mincer DL, Jialal I. Hashimoto Thyroiditis. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000336","article-title":"Type I interferons in host defence and inflammatory diseases","volume":"6","author":"Crow MK","year":"2019","unstructured":"Crow MK, Ronnblom L. Type I interferons in host defence and inflammatory diseases. Lupus Sci Med. 2019, 6:e000336. 10.1136\/lupus-2019-000336","journal-title":"Lupus Sci Med"},{"key":"ref41","article-title":"Systemic Lupus Erythematosus","author":"Justiz Vaillant AA","year":"2023","unstructured":"Justiz Vaillant AA, Goyal A, Varacallo M. Systemic Lupus Erythematosus. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref42","article-title":"Thyroid disease and autoimmune diseases","author":"Franco JS","year":"2013","unstructured":"Franco JS, Amaya-Amaya J, Anaya JM. Thyroid disease and autoimmune diseases. Autoimmunity: From Bench to Bedside. Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al. (ed): El Rosario University Press, Bogota, Colombia; 2013."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky DS","year":"2023","unstructured":"Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023, 19:509-24. 10.1038\/s41581-023-00720-1","journal-title":"Nat Rev Nephrol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100187","article-title":"Polyautoimmunity in systemic lupus erythematosus patients: new insights from a cross-sectional study","volume":"6","author":"Santos-Moreno P","year":"2023","unstructured":"Santos-Moreno P, Arias-Aponte J, Rodr\u00edguez-Vargas GS, et al.. Polyautoimmunity in systemic lupus erythematosus patients: new insights from a cross-sectional study. J Transl Autoimmun. 2023, 6:100187. 10.1016\/j.jtauto.2022.100187","journal-title":"J Transl Autoimmun"},{"key":"ref45","article-title":"Systemic lupus erythematosus","author":"Garc\u00eda-Carrasco M","year":"2013","unstructured":"Garc\u00eda-Carrasco M, Pinto CM, Poblano JCS, Morales IE, Cervera R, Anaya JM. Systemic lupus erythematosus. Autoimmunity: From Bench to Bedside. Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al. (ed): El Rosario University Press, Bogota, Colombia; 2013."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-72102-6_6","article-title":"Epidemiology of thyroid disorders","author":"Vanderpump MPJ","year":"2019","unstructured":"Vanderpump MPJ. Epidemiology of thyroid disorders. The Thyroid and Its Diseases. Luster M, Duntas L, Wartofsky L (ed): Springer, Cham; 2019. 75-85. 10.1007\/978-3-319-72102-6_6"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/s1550-8579(04)80006-8","article-title":"Gender differences in systemic lupus erythematosus","volume":"1","author":"Yacoub Wasef SZ","year":"2004","unstructured":"Yacoub Wasef SZ. Gender differences in systemic lupus erythematosus. Gend Med. 2004, 1:12-7. 10.1016\/s1550-8579(04)80006-8","journal-title":"Gend Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22196","article-title":"Autoimmune thyroid disease in women","volume":"325","author":"Mammen JS","year":"2021","unstructured":"Mammen JS, Cappola AR. Autoimmune thyroid disease in women. JAMA. 2021, 325:2392-3. 10.1001\/jama.2020.22196","journal-title":"JAMA"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2009.10.010","article-title":"Prevalence of thyroid dysfunctions in systemic lupus erythematosus","volume":"59","author":"Antonelli A","year":"2010","unstructured":"Antonelli A, Fallahi P, Mosca M, et al.. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism. 2010, 59:896-900. 10.1016\/j.metabol.2009.10.010","journal-title":"Metabolism"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.01.019","article-title":"Hypothyroidism among SLE patients: case-control study","volume":"15","author":"Watad A","year":"2016","unstructured":"Watad A, Mahroum N, Whitby A, Gertel S, Comaneshter D, Cohen AD, Amital H. Hypothyroidism among SLE patients: case-control study. Autoimmun Rev. 2016, 15:484-6. 10.1016\/j.autrev.2016.01.019","journal-title":"Autoimmun Rev"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2014.03.004","article-title":"Systemic lupus erythematosus and thyroid disease: a 10-year study","volume":"48","author":"Lin WY","year":"2015","unstructured":"Lin WY, Chang CL, Fu LS, Lin CH, Lin HK. Systemic lupus erythematosus and thyroid disease: a 10-year study. J Microbiol Immunol Infect. 2015, 48:676-83. 10.1016\/j.jmii.2014.03.004","journal-title":"J Microbiol Immunol Infect"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell JG","year":"2002","unstructured":"Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002, 87:489-99. 10.1210\/jcem.87.2.8182","journal-title":"J Clin Endocrinol Metab"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2016.11.008","article-title":"Systemic lupus erythematosus and thyroid disease - experience in a single medical center in Taiwan","volume":"52","author":"Liu YC","year":"2019","unstructured":"Liu YC, Lin WY, Tsai MC, Fu LS. Systemic lupus erythematosus and thyroid disease - experience in a single medical center in Taiwan. J Microbiol Immunol Infect. 2019, 52:480-6. 10.1016\/j.jmii.2016.11.008","journal-title":"J Microbiol Immunol Infect"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s44229-022-00017-8","article-title":"Thyroid dysfunction among patients with systemic lupus erythematosus in Saudi Arabia","volume":"4","author":"AL-Homood IA","year":"2022","unstructured":"AL-Homood IA, Alkhathami RA, Alenazi SK, Mohammed AA. Thyroid dysfunction among patients with systemic lupus erythematosus in Saudi Arabia. Dr. Sulaiman Al Habib Med J. 2022, 4:169-73. 10.1007\/s44229-022-00017-8","journal-title":"Dr. Sulaiman Al Habib Med J"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.4103\/jesnt.jesnt_6_22","article-title":"Prevalence of thyroid disorder in patients with systemic lupus erythematosus and patients with lupus nephritis","volume":"23","author":"Elshair HS","year":"2023","unstructured":"Elshair HS, Zeid MH, Deghady AA, Essa BY, Bondok ME. Prevalence of thyroid disorder in patients with systemic lupus erythematosus and patients with lupus nephritis. J Egyptian Soc Nephrol Transpl. 2023, 23:60-7. 10.4103\/jesnt.jesnt_6_22","journal-title":"J Egyptian Soc Nephrol Transpl"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2018.06.022","article-title":"Autoimmune thyroid disease in patients with systemic lupus erythematosus: a 7-year retrospective study in China","volume":"356","author":"Wei S","year":"2018","unstructured":"Wei S, Yang Z, Xie S, et al.. Autoimmune thyroid disease in patients with systemic lupus erythematosus: a 7-year retrospective study in China. Am J Med Sci. 2018, 356:344-9. 10.1016\/j.amjms.2018.06.022","journal-title":"Am J Med Sci"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.74750","article-title":"Quality of life in systemic lupus erythematosus and its measurement","volume":"56","author":"Olesi\u0144ska M","year":"2018","unstructured":"Olesi\u0144ska M, Saletra A. Quality of life in systemic lupus erythematosus and its measurement. Reumatologia. 2018, 56:45-54. 10.5114\/reum.2018.74750","journal-title":"Reumatologia"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-023-02718-0","article-title":"Quality of life, social support, and adherence in female patients with thyroid disorders","volume":"23","author":"Kollerits E","year":"2023","unstructured":"Kollerits E, Zsila \u00c1, Matuszka B. Quality of life, social support, and adherence in female patients with thyroid disorders. BMC Womens Health. 2023, 23:567. 10.1186\/s12905-023-02718-0","journal-title":"BMC Womens Health"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3818-y","article-title":"The importance of patient-centered care and co-creation of care for satisfaction with care and physical and social well-being of patients with multi-morbidity in the primary care setting","volume":"19","author":"Kuipers SJ","year":"2019","unstructured":"Kuipers SJ, Cramm JM, Nieboer AP. The importance of patient-centered care and co-creation of care for satisfaction with care and physical and social well-being of patients with multi-morbidity in the primary care setting. BMC Health Serv Res. 2019, 19:13. 10.1186\/s12913-018-3818-y","journal-title":"BMC Health Serv Res"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00212-9","article-title":"Systemic lupus erythematosus (SLE) therapy: the old and the new","volume":"7","author":"Basta F","year":"2020","unstructured":"Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic lupus erythematosus (SLE) therapy: the old and the new. Rheumatol Ther. 2020, 7:433-46. 10.1007\/s40744-020-00212-9","journal-title":"Rheumatol Ther"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2009.08.003","article-title":"Drugs that suppress TSH or cause central hypothyroidism","volume":"23","author":"Haugen BR","year":"2009","unstructured":"Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009, 23:793-800. 10.1016\/j.beem.2009.08.003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092709","article-title":"Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues","volume":"9","author":"Porta S","year":"2020","unstructured":"Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, Ruiz-Irastorza G. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020, 9:2709. 10.3390\/jcm9092709","journal-title":"J Clin Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1342915","article-title":"Commentary: azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial","volume":"15","author":"Mittal M","year":"2024","unstructured":"Mittal M, Rizvi A. Commentary: azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial. Front Endocrinol (Lausanne). 2024, 15:1342915. 10.3389\/fendo.2024.1342915","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1097\/IO9.0000000000000116","article-title":"Untapped potential of azathioprine in severe cases of Graves\u2019 disease: revolutionizing treatment","volume":"62","author":"Ali T","year":"2024","unstructured":"Ali T, Mansour HK, Alsharabi TSKA, Ali M, Fakih N. Untapped potential of azathioprine in severe cases of Graves\u2019 disease: revolutionizing treatment. Int J Surg Open. 2024, 62:428-30. 10.1097\/IO9.0000000000000116","journal-title":"Int J Surg Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/315222-connecting-the-dots-exploring-the-association-between-systemic-lupus-erythematosus-and-thyroid-disorders","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:33:38Z","timestamp":1732610018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/315222-connecting-the-dots-exploring-the-association-between-systemic-lupus-erythematosus-and-thyroid-disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":64,"URL":"https:\/\/doi.org\/10.7759\/cureus.74469","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,26]]}}}